title: Catechin protects against oxidative stress and inflammatory-mediated cardiotoxicity in adriamycin-treated rats.
abstract: Catechin has anti-inflammatory and antioxidative effects. Cardiotoxicity, which results from intense cardiac oxidative stress and inflammation, is the main limiting factor of the adriamycin use in the treatment of malignant tumors. Thus, the present study aimed to assess the antioxidant and anti-inflammatory effects of catechin on adriamycin-induced cardiotoxicity in rats. Forty-five rats were allocated to three groups: control group, adriamycin group and adriamycin + catechin group. We performed the following measurements: lipid peroxidation (MDA), catalase (CAT), glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) activities as well as, the expression of inflammatory cytokines genes namely nuclear factor kappa-B, tumor necrosis factor and inducible nitric oxide synthase. Catechin administration significantly decreased MDA level and significantly increased CAT, GSH-Px and SOD activities. Also, catechin significantly decreased the expression levels of inflammatory cytokines. Catechin provided cardioprotection on adriamycin-induced cardiotoxicity through their antioxidant and anti-inflammatory properties.
authors.affiliation: Cardiology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
authors.forename: Tarek A
authors.initials: TA
authors.lastname: Abd El-Aziz
authors.forename: Randa H
authors.initials: RH
authors.lastname: Mohamed
authors.forename: Heba F
authors.initials: HF
authors.lastname: Pasha
authors.forename: Hisham R
authors.initials: HR
authors.lastname: Abdel-Aziz
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology*; D054715:Cardiotoxins / Q000008:administration & dosage / Q000633:toxicity*; D002374:Catalase / Q000032:analysis; D002392:Catechin / Q000008:administration & dosage / Q000494:pharmacology*; D016207:Cytokines / Q000032:analysis; D004317:Doxorubicin / Q000008:administration & dosage / Q000633:toxicity*; D005979:Glutathione Peroxidase / Q000032:analysis; D015227:Lipid Peroxidation; D009206:Myocardium / Q000473:pathology; D018384:Oxidative Stress / Q000187:drug effects*; D051381:Rats; D013482:Superoxide Dismutase / Q000032:analysis
chemical_list: D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D054715:Cardiotoxins; D016207:Cytokines; D004317:Doxorubicin; D002392:Catechin; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase
references.citation: Toxicology. 2005 Apr 1;209(1):39-45
references.pmid: 15725512
references.citation: Cell Biol Toxicol. 2007 Jan;23(1):39-47
references.pmid: 17063376
references.citation: Circ Res. 2002 Jan 11;90(1):93-9
references.pmid: 11786524
references.citation: Anal Biochem. 1979 Jun;95(2):351-8
references.pmid: 36810
references.citation: J Biochem Mol Biol. 2006 Nov 30;39(6):759-65
references.pmid: 17129413
references.citation: Eur J Heart Fail. 2007 Feb;9(2):152-9
references.pmid: 16829193
references.citation: Iran J Pharm Res. 2011 Winter;10(1):89-96
references.pmid: 24363686
references.citation: Eur J Pharmacol. 1999 Jun 30;375(1-3):139-55
references.pmid: 10443572
references.citation: Circulation. 2002 Jan 29;105(4):490-6
references.pmid: 11815433
references.citation: J Lab Clin Med. 2005 Nov;146(5):299-303
references.pmid: 16242529
references.citation: Mol Pharmacol. 1997 Sep;52(3):465-72
references.pmid: 9281609
references.citation: Pancreas. 1997 Apr;14(3):276-9
references.pmid: 9094158
references.citation: Hypertension. 2001 Sep;38(3 Pt 2):576-80
references.pmid: 11566934
references.citation: Cancer. 1973 Aug;32(2):302-14
references.pmid: 4353012
references.citation: Lab Anim Sci. 1997 Oct;47(5):486-95
references.pmid: 9355091
references.citation: Biochem J. 2002 Nov 1;367(Pt 3):729-40
references.pmid: 12139490
references.citation: Eur J Pharmacol. 2002 Jan 2;434(1-2):1-7
references.pmid: 11755158
references.citation: J Pharmacol Exp Ther. 2000 Jul;294(1):396-401
references.pmid: 10871338
references.citation: BMC Pharmacol. 2003 Dec 20;3:16
references.pmid: 14687418
references.citation: Circulation. 2003 Nov 11;108(19):2423-9
references.pmid: 14568902
references.citation: Cancer Res. 2009 Jan 15;69(2):695-9
references.pmid: 19147586
references.citation: Mutat Res. 2003 Feb-Mar;523-524:201-8
references.pmid: 12628518
references.citation: Br J Cancer. 2003 Jul 21;89(2):357-62
references.pmid: 12865930
references.citation: Drugs Exp Clin Res. 2002;28(2-3):49-62
references.pmid: 12224378
references.citation: Biophys Chem. 1990 Apr;35(2-3):247-57
references.pmid: 2204444
references.citation: Methods Enzymol. 1981;77:325-33
references.pmid: 7329310
references.citation: Circulation. 2000 Oct 24;102(17):2105-10
references.pmid: 11044428
references.citation: J Mol Cell Cardiol. 2004 May;36(5):683-90
references.pmid: 15135663
references.citation: Braz J Med Biol Res. 2002 Nov;35(11):1379-87
references.pmid: 12426639
references.citation: Exp Clin Cardiol. 2002 Spring;7(1):35-9
references.pmid: 19644577
references.citation: Indian J Biochem Biophys. 1984 Apr;21(2):130-2
references.pmid: 6490072
references.citation: Biol Chem. 2002 Jan;383(1):101-5
references.pmid: 11928805